These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. | AstraZeneca has ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Last week, the immuno-oncology specialist revealed that part of the new setup will include CDMO services, as it will produce ...
Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...
Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production ...